



UNITED STATES PATENT AND TRADEMARK OFFICE

6
UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/527,788	11/02/2005	Sabine Wolf	63047(45107)	7480
21874	7590	12/03/2007	EXAMINER	
EDWARDS ANGELL PALMER & DODGE LLP			STEELE, AMBER D	
P.O. BOX 55874			ART UNIT	PAPER NUMBER
BOSTON, MA 02205			1639	
			MAIL DATE	DELIVERY MODE
			12/03/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)	
	10/527,788	WOLF ET AL.	
	Examiner	Art Unit	
	Amber D. Steele	1639	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on _____.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-13, 16, 17 and 21-26 is/are pending in the application.
 - 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) _____ is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) 1-13, 16, 17 and 21-26 are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Status of the Claims

1. The preliminary amendment to the claims received on March 11, 2005 amended claims 2-13 and 16-17, canceled claims 14-15 and 18-20, and added new claims 21-26.

Claims 1-13, 16-17, and 21-26 are currently pending and under consideration.

Election/Restrictions

2. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-6 and 21, drawn to a method for identifying the presence of a blood brain barrier (BBB) specific protein via a subtractive DNA library.

Group II, claim(s) 7-8, drawn to a BBB specific protein of SEQ ID NO: 5.

Group III, claim(s) 7-8, drawn to a BBB specific protein of SEQ ID NO: 14.

Group IV, claim(s) 7-8, drawn to a BBB specific protein of SEQ ID NO: 19.

Group V, claim(s) 7-8, drawn to a BBB specific protein of SEQ ID NO: 53.

Group VI, claim(s) 9-11, drawn to a method for identifying the presence of a BBB specific protein via isoelectric focusing.

Group VII, claim(s) 12-13, drawn to a BBB specific protein of SEQ ID NO: 23.

Group VIII, claim(s) 12-13, drawn to a BBB specific protein of SEQ ID NO: 27.

Group IX, claim(s) 12-13, drawn to a BBB specific protein of SEQ ID NO: 33.

Group X, claim(s) 16-17, drawn to a BBB specific agent (i.e. protein).

Group XI, claim(s) 22-24, drawn to a method for diagnosis using a BBB specific protein of SEQ ID NO: 4.

Group XII, claim(s) 22-24, drawn to a method for diagnosis using a BBB specific protein of SEQ ID NO: 6.

Group XIII, claim(s) 22-24, drawn to a method for diagnosis using a BBB specific protein of SEQ ID NO: 15.

Group XIV, claim(s) 22-24, drawn to a method for diagnosis using a BBB specific protein of SEQ ID NO: 22.

Group XV, claim(s) 22-24, drawn to a method for diagnosis using a BBB specific protein of SEQ ID NO: 23.

Group XVI, claim(s) 22-24, drawn to a method for diagnosis using a BBB specific protein of SEQ ID NO: 26.

Group XVII, claim(s) 22-24, drawn to a method for diagnosis using a BBB specific protein of SEQ ID NO: 32.

Group XVIII, claim(s) 22-24, drawn to a method for diagnosis using a BBB specific protein of SEQ ID NO: 35.

Group XIX, claim(s) 22-24, drawn to a method for diagnosis using a BBB specific protein of SEQ ID NO: 36.

Group XX, claim(s) 22-24, drawn to a method for diagnosis using a BBB specific protein of SEQ ID NO: 43.

Group XXI, claim(s) 22-24, drawn to a method for diagnosis using a BBB specific protein of SEQ ID NO: 49.

Group XXII, claim(s) 22-24, drawn to a method for diagnosis using a BBB specific protein of SEQ ID NO: 52.

Group XXIII, claim(s) 22-24, drawn to a method for diagnosis using a BBB specific protein of SEQ ID NO: 54.

Group XXIV, claim(s) 22-24, drawn to a method for diagnosis using a BBB specific protein of SEQ ID NO: 55.

Group XXV, claim(s) 25, drawn to a method for transporting a substance using a BBB specific protein.

Group XXVI, claim(s) 26, drawn to a method of diagnosis using a BBB specific protein.

3. The inventions listed as Groups I-XXVI do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the common technical feature is a BBB specific protein which is known in the art. In addition, the various SEQ ID NOS: of Groups II-V, VII-IX, and XI-XXIV do not share a common core structure and thus do not have a common technical feature.

Specifically, Kozarich et al. U.S. Patent 5,268,164 teach poplypeptides called receptor mediated permeabilizers (RMP) that increase the permeability of the blood brain barrier (BBB) and methods of making RMPs (please refer to the entire specification particularly the abstract; columns 2 and 4; and Examples). In addition, Kozarich et al. teach polypeptides with a core structure of SEQ ID NO: 1 and bradykinin analogues (i.e. A-7; please refer to column 2). Furthermore, Kozarich et al. teach that the RMPs are specific for B₂ receptors located on the surface of brain endothelial cells that form the blood brain barrier (please refer to column 4).

4. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

5. The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

6. Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

7. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Future Communications

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Amber D. Steele whose telephone number is 571-272-5538. The examiner can normally be reached on Monday through Friday 9:00AM-5:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Doug Schultz can be reached on 571-272-0763. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Amber D. Steele/
Patent Examiner
AU1639

November 26, 2007